Intuitive Surgical stock: Single-port robot drives new growth

Published on 11/09/2026 at 16:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Intuitive Surgical stock is drawing attention to faster single-port growth and a planned vessel-sealer filing. The platform remains small but expanding.

Single-Port Platform Expands Growth Options

Single-port procedures rose 55 percent in the third quarter, outpacing overall da Vinci procedure growth.
Intuitive Surgical placed a record 42 single-port systems and plans a US vessel-sealer submission in the fourth quarter.
Procedure growth and instrument revenue remain central tests as pricing actions approach.

Intuitive Surgical, US46120E6023, Illustration mit AI erstellt.

Intuitive Surgical is adding a new growth angle to its robotic-surgery model as the single-port platform gains traction. The company’s third-quarter earnings call on October 20, 2026, highlighted faster SP procedure growth, record placements and a planned regulatory step.

Single-Port Growth Accelerates

According to Intuitive Surgical's Q3 earnings transcript, SP procedures increased 55 percent year over year in the third quarter. Growth reached 50 percent in the United States and 40 percent in South Korea, the company's largest SP market.

Intuitive placed a record 42 SP systems during the quarter, lifting the installed base 42 percent from a year earlier to 487 systems across 27 countries. The platform is still a small part of the more than 13,200 da Vinci and Ion systems installed worldwide, but its faster expansion adds another avenue for utilization growth.

Vessel Sealer Is Next Catalyst

Management said adoption of the SP stapler is broadening and plans to submit the SP vessel sealer to US regulators in the fourth quarter. Intuitive considers the instrument a key enabler for broader SP adoption because it could support a wider range of procedures.

The recurring instruments business remains important to the investment case. Third-quarter instruments and accessories revenue rose 18 percent to 1.8 billion US dollars, while da Vinci instrument revenue per procedure reached about 1,860 US dollars, up from 1,800 US dollars a year earlier. Management also outlined pricing actions planned from the first half of 2027, creating a trade-off between wider access and revenue per procedure.